Trelegy Ellipta

RSS

fluticasone furoate / umeclidinium / vilanterol

Authorised
This medicine is authorised for use in the European Union.

Overview

Trelegy Ellipta is a medicine used to relieve the symptoms of moderate to severe chronic obstructive pulmonary disease (COPD). COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing.

Trelegy Ellipta is used in adults whose disease is not controlled well enough with a combination of inhaled medicines consisting of a long-acting beta-2 agonist plus either a corticosteroid or a long-acting muscarinic antagonist. Long-acting beta-2 agonists widen the airways; corticosteroids reduce inflammation in the airways and lungs; and muscarinic receptor antagonists cause the muscles of the airways to relax.

Trelegy Ellipta is used for maintenance (regular) treatment on a daily basis. It contains the active substances fluticasone furoate, umeclidinium bromide and vilanterol.

This EPAR was last updated on 24/05/2019

Authorisation details

Product details
Name
Trelegy Ellipta
Agency product number
EMEA/H/C/004363
Active substance
fluticasone furoate, umeclidinium bromide, vilanterol trifenatate
International non-proprietary name (INN) or common name
fluticasone furoate / umeclidinium / vilanterol
Therapeutic area (MeSH)
Pulmonary Disease, Chronic Obstructive
Anatomical therapeutic chemical (ATC) code
R03AL08
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
GlaxoSmithKline Trading Services
Revision
4
Date of issue of marketing authorisation valid throughout the European Union
15/11/2017
Contact address

Currabinny
Carrigaline
County Cork
Ireland

Product information

29/03/2019 Trelegy Ellipta - EMEA/H/C/004363 - N/0008

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Drugs for obstructive airway diseases

Therapeutic indication

Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist.

Assessment history

How useful was this page?

Add your rating
Average
1 rating
1 rating
1 rating
1 rating